2001 Fiscal Year Final Research Report Summary
Induction of specific cellular immunity to EBV-positive T- and NK-lymphomas
| Project/Area Number |
12670802
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Single-year Grants |
|---|
| Section | 一般 |
|---|
| Research Field |
Pediatrics
|
|---|
| Research Institution | Aichi Cancer Center |
|---|
Principal Investigator |
KUZUSHIMA Kiyotaka Aichi Cancer Center, Div. of Virology, Section head, 腫瘍ウイルス学部, 室長 (30311442)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
TSURUMI Tatsuya Aichi Cancer Center, Div. of Virology, Chief, 腫瘍ウイルス学部, 部長 (90172072)
|
|---|
| Project Period (FY) |
2000 – 2001
|
| Keywords | Epstein-Barr virus / CTL / HLA-A24 / MHC-peptide tetramer / lymphoma |
|---|
| Research Abstract |
EBV is associated with several malignant diseases, including a subset of lymphomas, nasopharyngeal carcinomas, Burkitt's lymphomas and immunoblastic lymphomas seen in immunocompromised hosts. We established an efficient approach for determination of CTL epitopes in the context of HLA A^*2402 molecules through multiple screenings, consisting of a computer-assisted algorithm, an in vitro MHC stabilization assay and an enzyme-linked immuno-spot (ELISPOT) assay. HLA A24 is the most frequently encountered HLA class I allele and the genotype is almost exclusively A^*2402. We first searched for candidate,peptides with the HLA A24-binding motif by a computer-assisted algorithm among EBV proteins reported to be targeted by specific CD8^+ T cells. We selected and synthesized 42 peptides after analyzing amino acid sequences of the 5 lytic and 6 latent cycle proteins. All of them functionally stabilized HLA A^*2402 molecules which had been expressed on the peptide transporter-deficient cell line T2. Next is screening of the peptides by ELISPOT assay for their recognition by bulk EBV-specific CD8^+ T cells, established from PBMCs of EBV-immune donors positive for HLA A24.-typing. We have identified 2 possible major lytic cycle EBV-specific CTL epitopes from the amino acid sequences of BRLF1 and BMLF1 and 1 from LMP2 presented by HLA A^*2402 molecules. The newly identified peptides should prove useful for detection and/or study of EBV-specific CD8^+ T cell responses among populations positive for HLA A^*2402. We produced HLA A^*2402tetramers-incorporating the 3 peptides and 2 known epitope peptide, one derived from EBNA3A (RYSIFFDYM), and the other derived from EBNA3B (TYSAGIVQI). All the 5 tetramers successfully stained various proportions of EBV-specific CD8+ T cells. The newly identified peptides should prove useful for detection and/or study of EBV-specific CD8^+ T cell responses among populations positive for HLAA^*2402.
|
-
-
-
-
-
-
-
-
[Publications] Hoshino Y, Kimura H, Kuzushima K, Tsurumi T, Nemoto, K, Kikuta A, Nishiyama Y, Kojima S, Matsuyama T, Morishima T: "Early intervention in post-transplant lymphoproliferative disorders based on Epsttransplant lymphoproliferative disorder"Bone Marrow Transplant. 26(2). 199-201 (2000)
Description
「研究成果報告書概要(欧文)」より
-
-
-
-
-
-
